静脉注射免疫球蛋白市场－全球产业规模、份额、趋势、机会、预测：按类型、应用、地区和竞争格局划分，2021-2031年

全球静脉注射免疫球蛋白市场预计将从 2025 年的 134.1 亿美元成长到 2031 年的 210.1 亿美元，复合年增长率为 7.77%。

静脉注射免疫球蛋白（IVIg）源自数千名健康捐血者的血浆，是治疗方法原发性免疫力缺乏缺陷和自体免疫疾病的重要选择。免疫力缺乏缺陷诊断率的不断上升以及全球人口老化对免疫调节的需求，进一步巩固了IVIg的市场基础。此外，IVIg在神经系统疾病领域的临床应用不断拓展，推动了其成长，超越了短期趋势和近期监管政策的变化。

然而，要确保获得足够的血浆原料以满足日益增长的全球需求，需要建立复杂且高成本的物流系统，这对整个产业构成了重大挑战。例如，根据澳洲国家血液管理局的报告，在2023-2024财年（2024年），澳洲发放了约930万克免疫球蛋白製剂。这凸显了供应链为满足消费需求所承受的巨大压力。因此，快速扩展血浆采集基础设施的挑战成为市场进一步成长的主要障碍。

市场驱动因素

市场成长的主要驱动因素是原发性和续发性免疫力缺乏缺陷疾病诊断数量的增加。随着医疗系统检测免疫功能障碍的能力不断提高，需要终身接受免疫球蛋白替代疗法以预防感染疾病的患者群体也不断扩大。这形成了一个稳定的需求基础，使得血浆分馏生产者持续扩大产能至关重要。例如，CSL有限公司在其截至2024年8月的财年年度报告中指出，其免疫球蛋白产品组合的销售额增长了20%，达到56.66亿美元，凸显了这些生物疗法对已确诊患者的重要性。

同时，静脉注射免疫球蛋白在治疗神经系统疾病（尤其是慢性脱髓鞘多发性神经炎，神经病变自体免疫发炎性脱髓鞘性多发性神经病变 (CIDP)）方面的需求不断增长，显着扩大了其治疗领域。该领域的监管核准正在加速其应用，并加剧对有限血浆资源的竞争。武田药品工业株式会社于2024年1月发布的新闻稿显示，III期临床试验数据显示，治疗组的復发率仅15.5%，而安慰剂组为31.7%，证实了其疗效。这项临床成功推动了财务成长，Griffols公司2024年生物製药销售额达到55.53亿欧元的报告便印证了这一点，而这主要得益于免疫球蛋白的强劲应用。

市场挑战

全球静脉注射免疫球蛋白（IVIg）市场面临着许多限制因素，其中之一是取得充足血浆原料需要高度资本密集的物流基础设施。与采用合成生产的製药产业不同，IVIg产业受限于人类捐血的生物学局限性以及采集、检测和运输所需的庞大基础设施。这种依赖导致供应链僵化，无法快速扩大产能以满足日益增长的国际自体免疫疾病和免疫力缺乏治疗需求，从而有效限制了市场成长。

因此，这种供应瓶颈阻碍了该产业利用诊断率上升所带来的机会。支援一名患者所需的原料数量庞大，而采集网路却以难以企及的速度不断扩张。血浆蛋白治疗协会在2024年指出，每年大约需要130份血浆捐赠才能治疗一名原发性免疫力缺乏患者。如此巨大的需求凸显了业务扩张中面临的重大物流挑战。随着临床需求的增长，该行业难以相应提高其采集能力，这直接影响了产品的供应和整体市场成长。

市场趋势

市场上的一项关键进展是血浆分馏产量的技术最佳化。由于原血浆来源有生物学限制，生产商正积极采用先进的分离技术，以最大限度地提高每次捐血中免疫球蛋白的回收率。这种对营运效率的关注使企业能够将产量线性成长与血浆采集量线性成长分开，从而实现更稳定的利润率和更强的供应韧性。例如，2024年2月，Griffols宣布其营运改善计画已使2023年12月的血浆每公升成本较2022年7月的尖峰时段降低了22%，这充分证明了提高产量技术的经济效益。

同时，在患者对便利性的需求以及支付方对经济高效治疗环境的需求的推动下，居家静脉注射免疫球蛋白（IVIg）疗法的普及正在迅速推进。这一趋势正在使治疗分散化，从住院机构转向专业的门诊和居家输液网络，从而实现灵活的治疗安排并降低感染风险。这种结构性变化正在推动远端输液领域独立服务提供者的成长。作为这项变更的佐证，Option Care Health在2024年10月发布的报告显示，其第三季收入净额达到12.785亿美元，年增17.0%，反映出市场对居家及其他场所输液服务的需求不断增长。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球静脉注射免疫球蛋白市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（IgG、IgA、IgM、IgE、IgD）
  • 外用（低丙种球蛋白血症、慢性脱髓鞘多发性神经炎（CIDP）、原发性免疫力缺乏、重症肌无力、多灶性运动神经病变及其他用途）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美静脉注射免疫球蛋白市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲静脉注射免疫球蛋白市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区静脉注射免疫球蛋白市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲静脉注射免疫球蛋白市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲静脉注射免疫球蛋白市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球静脉注射免疫球蛋白市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products Holdings Inc.
• CSL Behring
• Grifols SA
• Kedrion SpA
• Shanghai RAAS Blood Products Co. Ltd
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Baxter International Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Intravenous Immunoglobulin Market is projected to expand from USD 13.41 Billion in 2025 to USD 21.01 Billion by 2031, registering a compound annual growth rate of 7.77%. Derived from the pooled plasma of thousands of healthy donors, Intravenous Immunoglobulin (IVIg) serves as a critical treatment for patients suffering from primary immunodeficiency diseases and autoimmune disorders. The market's foundation is strengthened by the increasing prevalence of diagnosed immune deficiencies and an aging global demographic requiring immune modulation. Additionally, the broadening clinical use of IVIg for neurological conditions functions as a fundamental driver of growth, extending beyond temporary trends or immediate regulatory changes.

However, the industry faces substantial hurdles related to the intricate and expensive logistics necessary to secure enough source plasma to satisfy rising global demand. For instance, the National Blood Authority reported that in 2024, approximately 9.3 million grams of immunoglobulin products were issued in Australia during the 2023-24 fiscal year, underscoring the immense strain on supply chains to keep pace with consumption. Consequently, the challenge of rapidly expanding plasma collection infrastructure stands as a major obstacle to further market growth.

Market Driver

The primary catalyst for market growth is the increasing diagnosis of primary and secondary immunodeficiency disorders. As healthcare systems refine their ability to detect compromised immune function, a larger patient population requires lifelong immunoglobulin replacement therapies to prevent infections. This establishes a consistent demand baseline that necessitates continuous capacity expansion by plasma fractionators. For example, CSL Limited reported in their August 2024 Annual Report that immunoglobulin portfolio sales increased by 20% to $5,666 million, highlighting the critical need for these biological treatments among diagnosed patients.

Concurrently, the rising demand for intravenous immunoglobulin in treating neurological conditions, particularly autoimmune neuropathies such as Chronic Inflammatory Demyelinating Polyneuropathy, is significantly expanding the therapeutic landscape. Regulatory endorsements in this area are driving utilization, leading to higher competition for limited plasma resources. According to a January 2024 press release from Takeda, pivotal trial data showed a relapse rate of just 15.5% for patients on therapy compared to 31.7% for the placebo group, confirming its efficacy. This clinical success supports financial growth, as evidenced by Grifols reporting biopharmaceutical revenue of EUR 5,553 million in 2024, driven largely by strong immunoglobulin adoption.

Market Challenge

The Global Intravenous Immunoglobulin Market faces significant constraints due to the sophisticated and capital-intensive logistics needed to obtain adequate volumes of source plasma. Unlike pharmaceutical industries that utilize synthetic manufacturing, the IVIg sector is bound by the biological limitations of human donation and the extensive infrastructure required for collection, testing, and transport. This reliance results in a rigid supply chain where production capabilities cannot be rapidly scaled to meet the increasing international demand for autoimmune and immunodeficiency treatments, effectively limiting market expansion.

As a result, this supply bottleneck hinders the sector's capacity to leverage rising diagnosis rates. The amount of raw material necessary to support a single patient is extensive, placing constant pressure on collection networks to expand at a difficult pace. The Plasma Protein Therapeutics Association noted in 2024 that treating one patient with primary immune deficiency requires about 130 plasma donations per year. This high-volume requirement underscores the significant logistical challenges in scaling operations; as clinical demand rises, the industry finds it difficult to proportionally increase collection capacity, which directly impacts product availability and overall market growth.

Market Trends

A significant evolution in the market is the technological optimization of plasma fractionation yields. Confronted with the biological limitations of sourcing raw plasma, manufacturers are actively deploying advanced fractionation methods to maximize immunoglobulin protein recovery from each donation. This emphasis on operational efficiency enables companies to separate production volumes from the need for linear increases in plasma collection, thereby stabilizing margins and enhancing supply resilience. For instance, Grifols stated in February 2024 that their Operational Improvement Plan led to a 22% reduction in plasma cost per liter by December 2023 compared to the July 2022 peak, illustrating the financial benefits of these yield-improving technologies.

Simultaneously, there is a widespread shift toward the adoption of home-based IVIg infusion therapies, fueled by patient preference for convenience and payer demand for cost-efficient care settings. This trend decentralizes administration, moving treatment from inpatient hospitals to specialized ambulatory and home infusion networks that provide flexible scheduling and lower infection risks. This structural change is driving the growth of independent providers in the remote infusion space. As evidence of this shift, Option Care Health reported in October 2024 that third-quarter net revenue reached $1,278.5 million, a 17.0% increase year-over-year, reflecting the escalating demand for home and alternate site infusion services.

Key Market Players

• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products Holdings Inc.
• CSL Behring
• Grifols SA
• Kedrion SpA
• Shanghai RAAS Blood Products Co. Ltd
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Baxter International Inc

Report Scope

In this report, the Global Intravenous Immunoglobulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Intravenous Immunoglobulin Market, By Type

• IgG
• IgA
• IgM
• IgE
• IgD

Intravenous Immunoglobulin Market, By Application

• Hypogammaglobulinemia
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Primary Immunodeficiency Diseases
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• Other Applications

Intravenous Immunoglobulin Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intravenous Immunoglobulin Market.

Available Customizations:

Global Intravenous Immunoglobulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Intravenous Immunoglobulin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (IgG, IgA, IgM, IgE, IgD)
  • 5.2.2. By Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Intravenous Immunoglobulin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Intravenous Immunoglobulin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Intravenous Immunoglobulin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Intravenous Immunoglobulin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Intravenous Immunoglobulin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Intravenous Immunoglobulin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Intravenous Immunoglobulin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Intravenous Immunoglobulin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Intravenous Immunoglobulin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Intravenous Immunoglobulin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Intravenous Immunoglobulin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Intravenous Immunoglobulin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Intravenous Immunoglobulin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Intravenous Immunoglobulin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Intravenous Immunoglobulin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Intravenous Immunoglobulin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Intravenous Immunoglobulin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Intravenous Immunoglobulin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Intravenous Immunoglobulin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Intravenous Immunoglobulin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Intravenous Immunoglobulin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Intravenous Immunoglobulin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Intravenous Immunoglobulin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Intravenous Immunoglobulin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Intravenous Immunoglobulin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bio Products Laboratory Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Biotest AG
• 15.3. China Biologic Products Holdings Inc.
• 15.4. CSL Behring
• 15.5. Grifols SA
• 15.6. Kedrion SpA
• 15.7. Shanghai RAAS Blood Products Co. Ltd
• 15.8. Octapharma AG
• 15.9. Takeda Pharmaceutical Company Limited
• 15.10. Baxter International Inc

16. Strategic Recommendations

17. About Us & Disclaimer